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EDITORIAL
Time to treat polycystic kidney diseases like the neoplastic
disorders that they are
Polycystic kidney diseases are among the most com- branes. To test this idea, they utilized an in vitro model
mon single gene disorders that are potentially fatal. to examine the effect of a specific inhibitor of receptor
Genes on chromosomes 4, 6 and 16 encode proteins tyrosine kinase activation, EKI-785 [7]. In slices of kid-
called polycystins that, when mutated, cause renal tubule ney taken from Balb/c-bpk/bpk (BPK) mice with poly-
segments to expand relentlessly [1]. The massive enlarge- cystic kidneys the inhibitor diminished EGF receptor
ment of the kidneys due to the buildup of these fluid- autophosphorylation and strikingly decreased the in
filled cysts eventually leads to functional failure in a high vitro enlargement of cysts caused by EGF.
number of cases. The economic and emotional costs of In the current issue of Kidney International, Sweeney
polycystic diseases are enormous. and colleagues make a giant leap forward with the dra-
The neoplastic nature of renal cysts has been recog- matic finding that the administration of modest, non-
nized for several years [2]. The possibility that the prolif- toxic doses of EKI-785 to BPK mice prevented the en-
erating mural epithelial cells might be reasonable targets largement of the cysts and held renal function at rela-
of pharmacotherapy was addressed by Woo et al [3], who tively normal levels for as long as the drug was given
demonstrated that paclitaxel, an effective anti-neoplastic [8]. Withdrawal of EKI-785 led to prompt reawakening
drug for the treatment of ovarian carcinoma, also halted of cystic growth at a pace equal to that seen in the
the growth of renal cysts in mice with a recessive form untreated animals.
of polycystic kidney disease (C57 Bl/cpk/cpk). Unfortu- It is ironic that the abnormal placement of the EGF
nately, further studies have dampened the exploration receptors on the urinary surface of cyst epithelial cells
of paclitaxel because of a low therapeutic index in rodent has opened up an unexpected route for delivering the
cystic disease models other than the cpk mouse [4, 5]. EGF receptor inhibitor where it would have its greatest
Although mural cyst epithelial cells grow at a faster effect. The drug appears to be excreted in the urine and
rate than normal kidney parenchyma cells, they are not may be concentrated several-fold above that of plasma
malignant. Rather, they behave more like benign adeno- before it reaches the collecting ducts, the locus of cyst
mas. Agents that appear to increase the rate of prolifera- formation in the rapidly progressive recessive types of
tion include epidermal growth factor (EGF) and agonists polycystic kidney disease. Thus, kidney-effective doses
that stimulate the increased production of cyclic AMP of the drug could be administered without seriously
[abstract: Yamaguchi et al, J Am Soc Nephrol (in press)] blocking vital EGF receptors elsewhere in the body.
[6, 7]. Thus, rather than trying to destroy the mural The human type of recessive polycystic kidney disease
epithelial cells of cysts by bombardment with cytotoxic mimics in most respects that seen in the cpk and BPK
agents as employed in classical cancer chemotherapy, a rodent models. However, before one rushes to use EGF-
more reasonable strategy would be to interfere with the receptor blockers to treat children with recessive poly-
growth-promoting effects of the agonists. cystic kidney disease, it will be important to determine
Murcia, Sweeney, and Avner observed that EGF re- the gestational or post-partum age at which the growth-
ceptors appeared in increased density on the apical sur- promoting action of tyrosine kinase activation com-
faces of cells facing the lumens in collecting duct cysts mences. Other evidence suggests that in the early stages
in mice and humans with rapidly progressive polycystic of renal tubule development urinary EGF may be neces-
kidney disease that is recessively transmitted [6]. Thus, sary to hasten the maturation of collecting ducts [9].
EGF in the urine could more readily promote cell prolif- EGF administered between 3 to 9 days post-partum to
eration through tyrosine-kinase-mediated activation of cpk [10] and BPK [abstract; Nakanishi et al, J Am Soc
the mitogen-activated-protein kinase pathway than if the Nephrol (in press)] mice appears to ameliorate the dis-
receptors were confined to the basolateral plasma mem- ease, whereas the blockade of EGF activation of receptor
tyrosine kinase beginning on day 7 post-partum, as dem-
onstrated in the current study, impedes the enlargementKey words: polycystic disease, epithelial growth factor, cyst, tyrosine-
kinase activation. of cysts. Consequently, there may be a critical “window”
for the administration of the receptor tyrosine kinase 2000 by the International Society of Nephrology
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